公开(公告)号：US11875523B2

公开(公告)日：2024-01-16

申请号：US17286488

申请日：2019-09-20

Applicant: ShanghaiTech University

Inventor： Fupeng Chen ,  Heng Yu ,  Yajun Ha

IPC: G06K9/00 ,  G06T7/593 ,  G06F17/12

CPC classification number: G06T7/593 ,  G06F17/12 ,  G06T2207/10012 ,  G06T2207/20004 ,  G06T2207/20081

Abstract: The present disclosure provides an adaptive stereo matching optimization method, apparatus, and device, and a storage medium. The method includes: acquiring images of at least two perspectives of the same target scene, accordingly obtaining, through calculation, disparity value ranges corresponding to pixels in the target scene; and obtaining optimized depth value ranges by adjusting the disparity value ranges of the pixels in the target scene in real time through an adaptive stereo matching model; adjusting an execution cycle in the adaptive stereo matching model in real time through a DVFS algorithm according to a resource constraint condition of the processing system; and/or training on a plurality of scene image data sets through a convolutional neural network, so that the specific function parameters in the adaptive stereo matching model are correspondingly adjusted in real time according to the acquired different scene images.

公开(公告)号：US11773145B2

公开(公告)日：2023-10-03

申请号：US16632299

申请日：2018-07-20

Applicant: ShanghaiTech University

Inventor： Jia Liu ,  Biao Jiang

IPC: C07K14/33 ,  C07K19/00 ,  A61K38/00

CPC classification number: C07K14/33 ,  C07K19/00 ,  A61K38/00 ,  C07K2319/55 ,  C07K2319/81

Abstract: Provided are chimeric polypeptides that include one or more zinc finger motifs fused to a therapeutic peptide such as botulinum neurotoxins (BoNTs). The zinc finger motif may be located at the C-terminal side of the BoNT and the chimeric polypeptide can optionally include two or more such zinc finger motifs. It said the disclosed chimeric polypeptides can be efficiently delivered to a subject transdermally.

公开(公告)号：US20230287107A1

公开(公告)日：2023-09-14

申请号：US17628869

申请日：2019-07-23

Applicant: ShanghaiTech University

Inventor： Guang YANG ,  Min QIANG

IPC: C07K16/28 ,  A61P9/10

CPC classification number: C07K16/28 ,  A61P9/10 ,  C07K2317/565 ,  C07K2317/52

Abstract: The present technology relates generally to compositions and methods of preventing or treating ischemic stroke. The present technology also relates to administering the anti-ASIC1a antibodies in effective amounts to treat a subject suffering from, or predisposed to, ischemic stroke.

公开(公告)号：US20230203022A1

公开(公告)日：2023-06-29

申请号：US17922124

申请日：2021-04-29

Applicant: Shanghaitech University

Inventor： Xiaobao YANG ,  Biao JIANG ,  Linyi LIU ,  Chaowei REN ,  Xing QIU ,  Haixia LIU ,  Ning SUN ,  Renhong SUN

IPC: C07D405/14 ,  A61K45/06 ,  C07D417/14 ,  C07D401/14 ,  C07D453/02 ,  C07D409/14

CPC classification number: C07D405/14 ,  A61K45/06 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14 ,  C07D453/02

Abstract: The present disclosure relates to compounds of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof, and uses thereof. The present disclosure also relates to pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or a salt, enantiomer, stereoisomer, solvate, or polymorph thereof, and use thereof. A series of compounds designed and synthesized by the present disclosure can effectively prevent and/or treat diseases or disorders associated with TNF-a.

公开(公告)号：US20230196079A1

公开(公告)日：2023-06-22

申请号：US18009341

申请日：2022-08-05

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Hongtu ZHANG ,  Yuhao SHU ,  Yajun HA

IPC: G06N3/0464 ,  G06F5/16

CPC classification number: G06N3/0464 ,  G06F5/16

Abstract: An enhanced dynamic random access memory (eDRAM)-based computing-in-memory (CIM) convolutional neural network (CNN) accelerator comprises four P2ARAM blocks, where each of the P2ARAM blocks includes a 5T1C ping-pong eDRAM bit cell array composed of 64×16 5T1C ping-pong eDRAM bit cells. In each of the P2ARAM blocks, 64×2 digital time converters convert a 4-bit activation value into different pulse widths from a row direction and input the pulse widths into the 5T1C ping-pong eDRAM bit cell array for calculation. A total of 16×2 convolution results are output in a column direction of the 5T1C ping-pong eDRAM bit cell array. The CNN accelerator uses the 5T1C ping-pong eDRAM bit cells to perform multi-bit storage and convolution in parallel. An S2M-ADC scheme is proposed to allot an area of an input sampling capacitor of an ABL to sign-numerical SAR ADC units of a C-DAC array without adding area overhead.

公开(公告)号：US11655238B2

公开(公告)日：2023-05-23

申请号：US17295227

申请日：2019-11-20

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Zihe Rao ,  Jun Li ,  Bing Zhang ,  Haitao Yang

IPC: C07D403/04 ,  C07D207/327 ,  C07D231/14 ,  C07D233/90 ,  C07D249/10 ,  C07D333/38 ,  C07D401/04 ,  C07D405/04

CPC classification number: C07D403/04 ,  C07D207/327 ,  C07D231/14 ,  C07D233/90 ,  C07D249/10 ,  C07D333/38 ,  C07D401/04 ,  C07D405/04

Abstract: The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.

公开(公告)号：US20230094769A1

公开(公告)日：2023-03-30

申请号：US17862354

申请日：2022-07-11

Applicant: ShanghaiTech University

Inventor： Jia Chen ,  Bei Yang ,  Li Yang ,  Xingxu Huang ,  Lijie Wang

IPC: C12N15/10 ,  C12N9/22 ,  C12N9/50 ,  C12N9/78 ,  C12N15/11

Abstract: Provided are fusion proteins and related molecules useful for conducting base editing with reduced or no off-target mutations. The fusion protein may include a first fragment comprising a nucleobase deaminase or a catalytic domain thereof, a second fragment comprising a nucleobase deaminase inhibitor, and a protease cleavage site between the first fragment and the second fragment. Also provided are improved prime editing systems, including prime editing guide RNA with improved stability.

公开(公告)号：US11615547B2

公开(公告)日：2023-03-28

申请号：US16877471

申请日：2020-05-18

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Yingliang Zhang ,  Guli Zhang ,  Zhiru Shi

IPC: G06T7/557 ,  G06F17/18 ,  G06K9/62 ,  G06N3/08 ,  G06T15/50

Abstract: A light field image processing method is disclosed for removing occluding foreground and blurring uninterested objects, by differentiating objects located at different depths of field and objects belonging to distinct categories, to create see-through effects. In various embodiments, the image processing method may blur a background object behind a specified object of interest. The image processing method may also at least partially remove from the rendered image any occluding object that may prevent a viewer from viewing the object of interest. The image processing method may further blur areas of the rendered image that represent an object in the light field other than the object of interest. The method includes steps of constructing a light field weight function comprising a depth component and a semantic component, where the weight function assigns a ray in the light field with a weight; and conducting light field rendering using the weight function.

公开(公告)号：US11464765B2

公开(公告)日：2022-10-11

申请号：US17402006

申请日：2021-08-13

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Haitao Yang ,  Zhenming Jin ,  Xiuna Yang ,  Yao Zhao ,  Zihe Rao

IPC: A61K31/41 ,  A61K31/4439 ,  A61P31/14

Abstract: Disclosed is a use of an N-substituted pyridyl benzisoselazolone compound. The use is particularly a use in the preparation of a medicament for treating and/or preventing a disease caused by coronavirus. The present disclosure surprisingly found that the N-substituted pyridyl benzisoselazolone compound, such as ebselen, can significantly inhibit the activity of the main protease of a coronavirus and the intracellular replication capability of SARS-CoV-2, which can be used for treating a disease caused by coronavirus.

公开(公告)号：US20220275097A1

公开(公告)日：2022-09-01

申请号：US17623792

申请日：2019-07-02

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Guang YANG ,  Pingdong TAO

IPC: C07K16/28 ,  A61P3/04

Abstract: The present technology relates generally to compositions and methods of preventing or treating diseases associated with mutantleptin receptors, leptin deficiency or leptin dysfunction. The present technology also relates to administering the anti-leptin receptor antibodies in effective amounts to treat a subject suffering from, or predisposed to, a disease associated with mutant leptin receptors, obesity, leptin deficiency, leptin resistance, and/or hypoleptinemia.